Product Information
METFORMIN HCL 850 MG TABLET is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.0240 per EA under NDC 00378718605. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jan 25, 2002. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
850 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378718605
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA075973FDA Approved
1/25/2002
TE Code
AB
On Market Since
6/3/2010
Pharmacological Classes
Price Statistics
The NADAC for METFORMIN HCL 850 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 37.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0240 per EA |
|---|---|
| All-time high | $0.0436 (Feb 12, 2014) |
| All-time low | $0.0196 (May 22, 2024) |
| 52-week high | $0.0248 |
| 52-week low | $0.0224 |
| Median price | $0.0293 |
| Average price | $0.0297 |
| Largest weekly change | +26.0% (Jun 19, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
metformin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METFORMIN HCL 850 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METFORMIN HCL 850 MG TABLET, manufactured by Mylan Pharmaceuticals Inc., is $0.0240 per EA (NDC 00378718605), effective Sep 30, 2026.
How has the price of METFORMIN HCL 850 MG TABLET changed over time?
Over the history we have for it, the NADAC for METFORMIN HCL 850 MG TABLET has declined 37.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for METFORMIN HCL 850 MG TABLET?
Since Nov 28, 2013, the NADAC for METFORMIN HCL 850 MG TABLET has ranged from a low of $0.0196 (May 22, 2024) to a high of $0.0436 (Feb 12, 2014), with a median of $0.0293 per EA.
Are there cheaper alternatives to METFORMIN HCL 850 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as METFORMIN HCL 850 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures METFORMIN HCL 850 MG TABLET?
METFORMIN HCL 850 MG TABLET (NDC 00378718605) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.